On November 1, 2024, Novavax, Inc. entered into a Termination and Settlement Agreement with the UK Health Security Agency, effectively resolving disputes related to the Amended and Restated SARS-COV-2 Vaccine Supply Agreement dated July 1, 2022. The settlement includes Novavax's commitment to refund $123.8 million to the Authority in quarterly installments over three years, with the option to avoid interest by accelerating payments. The first installment is due on November 30, 2024. This agreement concludes the obligations and claims of both parties under the previous supply agreement.

On November 1, 2024, Novavax, Inc. entered into a Termination and Settlement Agreement with the UK Health Security Agency, effectively resolving disputes related to the Amended and Restated SARS-COV-2 Vaccine Supply Agreement dated July 1, 2022. The settlement includes Novavax's commitment to refund $123.8 million to the Authority in quarterly installments over three years, with the option to avoid interest by accelerating payments. The first installment is due on November 30, 2024. This agreement concludes the obligations and claims of both parties under the previous supply agreement.